Harmony Biosciences Holdings, Inc. (HRMY) Q2 2026 Earnings Call Transcript

SA Transcripts 161.46K Followers Follow Harmony Biosciences Holdings, Inc. ( HRMY ) Q2 2026 Earnings Call August 4, 2026 8:30 AM EDT Company Participants Brennan Doyle - VP & Head of Investor Relations Jeffrey Dayno - President, CEO & Director Adam Zaeske - Executive VP & Chief Commercial Officer Kumar Budur - Executive VP and Chief Medical & Scientific Officer Peter Anastasiou - Chief Operating Officer Stephen Mollichella - Senior VP, Controller & Interim Principal Financial Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division David Hoang - Deutsche Bank AG, Research Division Graig Suvannavejh - Mizuho Securities USA LLC, Research Division David Amsellem - Piper Sandler & Co., Research Division Ami Fadia - Needham & Company, LLC, Research Division Luis Santos - H.C. Wainwright & Co, LLC, Research Division Danielle Brill Bongero - Truist Securities, Inc., Research Division Presentation Operator Good morning, everyone. My name is Bo, and I will be your conference operator today. At this time, I would like to welcome everyone to the Harmony Biosciences Second Quarter Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions] I would now like to turn the call over to Mr. Brennan Doyle, Head of Investor Relations. Please go ahead, sir. Brennan Doyle VP & Head of Investor Relations Good morning, everyone, and thank you for joining us today as we review Harmony Biosciences' second quarter 2026 financial results and provide a business update. Before we start, I encourage everyone to go to the Investors section of our website to find the materials that accompany today's discussion, including a reconciliation of our GAAP to non-GAAP financial measures. At this stage of our life cycle, we believe non-GAAP financial results better represent the underlying business performance. Our speakers on today's call are Dr. Jeffrey Dayno, President and CEO; Adam Zaeske, Chief Commercial Officer; Dr. Kumar Budur, Chief Medical and Scientific Officer; Peter Anastasiou, Chief